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Abstract
Atrial fibrillation (AF) prevalence increases with age; > 80% of US adults with AF are aged ≥ 65 years. Compare the risk 
of stroke/systemic embolism (SE), major bleeding (MB), net clinical outcome (NCO), and major adverse cardiac events 
(MACE) among elderly non-valvular AF (NVAF) Medicare patients prescribed direct oral anticoagulants (DOACs) vs 
warfarin. NVAF patients aged ≥ 65 years who initiated DOACs (apixaban, dabigatran, and rivaroxaban) or warfarin were 
selected from 01JAN2013-31DEC2015 in CMS Medicare data. Propensity score matching was used to balance DOAC and 
warfarin cohorts. Cox proportional hazards models estimated the risk of stroke/SE, MB, NCO, and MACE. 37,525 apixa-
ban–warfarin, 18,131 dabigatran–warfarin, and 55,359 rivaroxaban–warfarin pairs were included. Compared to warfarin, 
apixaban (HR: 0.69; 95% CI 0.59–0.81) and rivaroxaban (HR: 0.82; 95% CI 0.73–0.91) had lower risk of stroke/SE, and 
dabigatran (HR: 0.88; 95% CI 0.72–1.07) had similar risk of stroke/SE. Apixaban (MB: HR: 0.61; 95% CI 0.57–0.67; NCO: 
HR: 0.64; 95% CI 0.60–0.69) and dabigatran (MB: HR: 0.79; 95% CI 0.71–0.89; NCO: HR: 0.84; 95% CI 0.76–0.93) had 
lower risk of MB and NCO, and rivaroxaban had higher risk of MB (HR: 1.08; 95% CI 1.02–1.14) and similar risk of NCO 
(HR: 1.04; 95% CI 0.99–1.09). Compared to warfarin, apixaban had a lower risk for stroke/SE, MB, and NCO; dabigatran 
had a lower risk of MB and NCO; and rivaroxaban had a lower risk of stroke/SE but higher risk of MB. All DOACs had 
lower risk of MACE compared to warfarin.
Keywords Apixaban · Dabigatran · Rivaroxaban · Warfarin · Non-valvular atrial fibrillation · Medicare
Highlights
• The prevalence of NVAF and risk of stroke increase with 
age.
• Few studies have compared DOACs to warfarin among 
elderly NVAF patients regarding such outcomes.
• This study showed that compared to warfarin, all DOACs 
were associated with lower risk of MACE, and there 
were varying rates of stroke/SE, MB, and NCO between 
the individual DOACs and warfarin.
• The findings warrant more studies to better understand 
effectiveness and safety profiles in the elderly NVAF 
population.
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Introduction
The 2010 Global Burden of Disease Study estimated the 
worldwide age-adjusted prevalence of atrial fibrillation 
(AF) at 596 per 100,000 men and 373 per 100,000 women, 
equating to 33.5 million individuals (20.9 and 12.6 mil-
lion men and women, respectively) [1]. In the United 
States, the estimated prevalence of AF is 3–5 million [2, 
3]. The proportion of AF patients was found to increase 
sharply with age, especially in people aged ≥ 65 years, 
who account for three-quarters of the AF population [3].
Patients with AF diagnoses are at a nearly fivefold 
greater risk of stroke [4]. Moreover, the AF-attributable 
risk for ischemic stroke is age-dependent and increases 
from 4.6 to 7.9% to > 10% among patients aged 50–59, 
60–69, and ≥ 70 years, respectively [4]. Hence, the stroke 
risk stratification schema  CHA2DS2-VASc score considers 
older age (65–74 and ≥ 75 years) as a risk factor for stroke 
and thromboembolism in AF patients [5].
Oral anticoagulants (OACs) prevent stroke and systemic 
embolism (SE) among AF patients; they are recommended 
by the American College of Cardiology (ACC) and the 
American Heart Association (AHA) guidelines for patients 
with non-valvular AF (NVAF) and prior stroke, transient 
ischemic attack (TIA), or a  CHA2DS2-VASc score ≥ 2 
[6]. Warfarin, a vitamin K antagonist (VKA), has been 
used for stroke prevention among AF patients for decades. 
However, the narrow therapeutic window and increased 
risk of bleeding have hindered use, especially among the 
elderly [6].
In recent years, randomized clinical trials have dem-
onstrated that compared to warfarin, direct OACs 
(DOACs)—including apixaban, dabigatran, edoxaban, 
and rivaroxaban—were all associated with similar to lower 
risk of stroke/SE and major bleeding (MB) among elderly 
patients [7–9]. Introduced in 2008, the Fit-fOR-The-Aged 
(FORTA) classification is the first system with both nega-
tive (harmful or critical drugs: D and C labels) and posi-
tive (beneficial drugs: A and B labels) labelling at the indi-
vidual drug and drug group levels. Based on FORTA and 
the Delphi process, warfarin, dabigatran, edoxaban, and 
rivaroxaban were labelled B (beneficial; safely and effec-
tively treat AF), and apixaban was labeled A (absolutely; 
most beneficial risk–benefit ratio) for the treatment of AF 
patients aged > 65 years [10].
Using the largest US claims database of elderly patients, 
we evaluated real-world comparative risks of stroke/SE, 
MB, net clinical outcomes (stroke/SE or MB [NCO]), 
and major adverse cardiac events (MACE) among NVAF 
patients who initiated either DOACs (apixaban, dabi-
gatran, and rivaroxaban) or warfarin. This study added 
more recent data and additional outcome measures to our 
previous study, which provides comprehensive and current 
evidence to help prevent stroke among the elderly NVAF 
population [11]. The results also supplement clinical trials 
and add key information to real-world literature.
Methods
Data source
This retrospective observational study used the fee-for-ser-
vice (FFS) US Centers for Medicare & Medicaid Services 
(CMS) data from 01JAN2012-31DEC2015. This dataset is 
composed of adults aged ≥ 65 years, certain young people 
with disabilities, and people with end-stage renal disease. 
As of 2015, > 38 million beneficiaries were enrolled in this 
insurance [12]. The data include institutional (inpatient, 
skilled nursing facility, home health, hospice, and hospital 
outpatient) and non-institutional (physician/supplier–carrier 
and durable medical equipment) claims and Part D prescrip-
tion claims, coded using International Classification of Dis-
eases, Ninth/Tenth Revision, Clinical Modification (ICD-
9/10-CM) diagnosis and procedure codes, the Health Care 
Common Procedure Coding System, Current Procedural 
Terminology codes, and National Drug Codes [13].
Patient selection
AF (ICD-9-CM: 427.31 or ICD-10-CM: I48.0-I48.2, I48.91) 
patients aged ≥ 65 years with ≥ 1 pharmacy claim for apixa-
ban, dabigatran, edoxaban, rivaroxaban, or warfarin between 
01JAN2013-31DEC2015 (identification period) were 
selected. The first DOAC claim date during the identifica-
tion period was designated as the index date for patients with 
any DOAC claim; the first warfarin prescription date was 
designated as the index date for those without a DOAC claim 
[14]. Patients were also required to have continuous health 
plan enrollment with both medical and pharmacy benefits 
for the 12-month pre-index (baseline) period.
To select OAC treatment-naïve patients, those with 
any OAC claim during the baseline period were excluded. 
Patients with evidence of valvular heart disease or tran-
sient AF during the baseline period were also excluded. To 
omit OAC use for the treatment or prophylaxis of venous 
thromboembolism (VTE), patients with VTE in the baseline 
period or who had hip or knee replacement surgery within 6 
weeks prior to the index date were excluded. Detailed selec-
tion criteria appear in Fig. 1.
Outcome measures
The primary outcomes were the occurrence of stroke/SE and 
MB, identified by hospitalizations with stroke/SE or MB as 
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the principal diagnosis. Stroke/SE was further categorized 
by ischemic stroke, hemorrhagic stroke, and SE; MB was 
categorized by gastrointestinal (GI) bleeding, intracranial 
hemorrhage (ICH), and MB at other key sites [15, 16].
The secondary outcomes were NCO (a composite of 
stroke/SE and MB) and MACE, comprised of stroke (hem-
orrhagic and ischemic stroke), myocardial infarction (MI), 
and all-cause death. Claims databases cannot evaluate car-
diovascular-related death, so the MACE definition included 
all-cause death.
Patients were censored at the earliest of the discontinua-
tion date of the index treatment (no evidence of a prescrip-
tion for 30 days from the last day of the index medication 
days’ of supply), date of switch from the index drug to 
another OAC (a prescription for an OAC other than the index 
drug within 30 days before or after the discontinuation date), 
date of death, end of continuous enrollment, or end of study.
Statistical methods
One-to-one propensity score matching (PSM) was conducted 
between DOACs and warfarin (apixaban versus warfarin, 
dabigatran versus warfarin, and rivaroxaban versus warfarin) 
to control for potential confounders such as baseline demo-
graphics and clinical characteristics.
Using established methodology, propensity scores 
were generated by logistic regression. Age, sex, US geo-
graphic region, Charlson comorbidity index (CCI) [17], 
 CHA2DS2-VASc, and HAS-BLED scores, prior bleeding and 
stroke, comorbidities, baseline co-medications, and baseline 
inpatient visits were included in the models as covariates. 
The nearest neighbor without replacement method and a cal-
iper of 0.01 were implemented in the PSM [18]. After PSM, 
the balance of covariates was checked based on standardized 
differences, with a threshold of 10% [19].
For post-PSM cohorts, the incidence of primary and sec-
ondary outcomes was calculated as the number of events per 
100 person-years.
Cox proportional hazards models with robust sandwich 
estimates were used to evaluate the hazard ratios (HRs) of 
stroke/SE, MB, NCO, and MACE in each matched cohort 
[18]. After ensuring all the matched baseline covariates were 
balanced post-PSM, OAC treatment was included in the Cox 
models as the only independent variable.
Sensitivity analysis was conducted wherein patients were 
censored at 6 months of follow-up, creating more balance 
between cohorts.
Statistical analyses were performed using the Statistical 
Analysis System (SAS) Version 9.3 (Cary, NC).
Results
The study included eligible 198,171 patients; 81,410 (41.1%) 
were prescribed warfarin, 38,466 (19.4%) apixaban, 18,162 
(9.2%) dabigatran, and 60,133 (30.3%) rivaroxaban (Fig. 1). 
Edoxaban was excluded due to small sample size (N = 150). 
Before PSM, patients who initiated warfarin were older with 
Fig. 1  Patient selection criteria Paents with ≥1 pharmacy claim for apixaban, rivaroxaban, dabigatran, edoxaban, or warfarin during the 
idenficaon period (01JAN2013-31DEC2015). 
N = 2,639,095
Paents who were aged ≥65 years on the index date and had connuous health plan enrollment with medical and 
pharmacy benefits for ≥ 12 months pre-index date.
N = 1,438,300
Paents with ≥1 medical claim for AF (ICD-9-CM code 427.31; ICD-10-CM code: I480-I482, I4891) prior to/on the index 
date.
N = 1,351,970
Excluded paents with valvular heart disease, transient AF, venous thromboembolism, or a valve replacement 
procedure 12 months prior to the index date; indicaon of pregnancy during the study period; or hip/knee 
replacement surgery within 6 weeks prior to the index date.
N = 755,266
Excluded paents with a pharmacy claim for warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban  during the 
baseline period.
N = 203,357
Excluded paents with >1 OAC treatment on the index date or follow-up period equal to zero.
N = 198,321
Eligible paents for analysis (Total N = 198,321)
Apixaban = 38,466          Dabigatran = 18,162          Rivaroxaban = 60,133          Warfarin = 81,410          Edoxaban* = 150
Propensity Score Matched Paents
Warfarin-Apixaban=  37,525                    Warfarin-Dabigatran= 18,131                    Warfarin-Rivaroxaban= 55,359
*Edoxaban was not included in the analysis given the small sample size.
AF: atrial fibrillaon; ICD-9-CM: Internaonal Classificaon of Diseases, Ninth Revision, Clinical Modificaon;
ICD-10-CM: Internaonal Classificaon of Diseases, Tenth Revision, Clinical Modificaon; OAC: oral ancoagulant.
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a mean age of 79 years, followed by those who initiated 
apixaban (78 years), rivaroxaban (78 years), and dabigatran 
(77 years). In addition, warfarin patients also had higher CCI 
and  CHA2DS2-VASc scores than DOAC patients (Table 1).
Through PSM, 37,525 apixaban, 18,131 dabigatran, and 
55,359 rivaroxaban patients were separately matched to 
warfarin patients. Baseline characteristics were balanced 
after matching with mean standardized differences < 10%. 
For the matched cohorts, the means were: age: 77–78 years, 
 CHA2DS2-VASc scores: 4.4–4.6, and HAS-BLED scores: 
3.2–3.4 (Table 2). Patient data were assessed for a mean 
duration of 8–10 months. 71%, 80%, and 66% of patients 
were prescribed the standard dose of DOAC (apixaban 5 mg, 
dabigatran 150 mg, and rivaroxaban 20 mg), respectively.
Stroke/SE and MB
Compared to warfarin, apixaban (HR: 0.69; 95% confidence 
interval [CI] 0.59–0.81, p < 0.001) and rivaroxaban (HR: 
0.82; 95% CI 0.73–0.91, p < 0.001) were associated with a 
significantly lower risk of stroke/SE ; dabigatran (HR: 0.88; 
95% CI 0.72–1.07, p = 0.206) was associated with a non-
significantly lower risk of stroke/SE (Fig. 2). All DOACs 
were associated with a lower risk of hemorrhagic stroke 
versus warfarin.
Compared to warfarin, apixaban (HR: 0.61; 95% CI 
0.57–0.67, p < 0.001), and dabigatran (HR: 0.79; 95% CI 
0.71–0.89, p < 0.001) were associated with a significantly 
lower risk of MB, and rivaroxaban (HR: 1.08; 95% CI 
1.02–1.14, p = 0.006) was associated with a higher risk of 
MB, mainly due to GI bleeding (Fig. 2). All DOACs were 
associated with a lower risk of ICH versus warfarin.
NCO and MACE
As a composite of stroke/SE and MB, the risk of NCO was 
significantly lower than warfarin for apixaban (HR: 0.64; 
95% CI 0.60–0.69, p < 0.001) and dabigatran, (HR: 0.84; 
95% CI 0.76–0.93, p = 0.001) but similar for rivaroxaban 
(HR: 1.04; 95% CI 0.99–1.09, p = 0.169) (Fig. 3).
Compared to warfarin, all DOACs were associated 
with a lower risk of MACE (apixaban: HR: 0.70; 95% 
CI 0.67–0.74, p < 0.001; dabigatran: HR: 0.76; 95% CI 
0.71–0.82, p < 0.001; rivaroxaban: HR: 0.83; 95% CI 
0.80–0.86, p < 0.001; Fig. 3).
Sensitivity analysis
In the sensitivity analysis wherein the follow-up period was 
censored at 6 months, the results were consistent with the 
main analysis (Supplemental Table 1).
Discussion
Using Medicare FFS data from 2012 to 2015, this study 
showed that compared to warfarin among elderly patients 
with NVAF, apixaban was associated with significant 
lower risks of stroke/SE, MB, NCO, and MACE. Dabi-
gatran was associated with significantly lower risks of MB, 
NCO, and MACE as well as a numerically lower risk of 
stroke/SE. Rivaroxaban was associated with lower risks 
of stroke/SE and MACE, but higher MB and numerically 
higher NCO risks compared to warfarin.
The study results supplement RCT findings for apixa-
ban, dabigatran, and rivaroxaban compared to warfarin and 
their corresponding age subgroup analyses [20–25]. In the 
RE-LY trial, patients (overall and ≥ 75 years) with 150 mg 
dabigatran had lower rates of stroke/SE and similar rates 
of MB compared to warfarin [20, 23]. In this real-world 
study among NVAF patients aged ≥ 65 years, 150 mg and 
75 mg dabigatran showed numerically lower stroke/SE and 
significantly lower MB risks versus warfarin. Although 
NCO was not studied in the RE-LY trial’s elderly group, 
overall dabigatran and warfarin patient analysis demon-
strated that compared to warfarin, 150 mg twice-daily 
dabigatran was associated with a non-significantly lower 
risk of net clinical benefit (a composite of stroke/SE, pul-
monary embolism, MI, death, and MB) [20]. In this study, 
elderly dabigatran patients were associated with signifi-
cantly lower NCO and MACE risks than warfarin patients.
In the ARISTOTLE trial, apixaban was associated 
with lower rates of stroke/SE, MB, and net clinical events 
(stroke/SE, MB, and all-cause death) compared to warfarin 
among all patients and patients aged ≥ 65 years [22, 25]. 
This study found consistent trends. In the ROCKET AF 
trial, rivaroxaban was associated with a non-inferior rate 
of stroke/SE and similar rate of MB compared to warfarin 
[21]. Among patients aged ≥ 75 years, 20 and 15 mg daily 
rivaroxaban showed a numerically lower risk of stroke/SE 
but a higher risk of MB compared to warfarin [24]. This 
study found similar trends between rivaroxaban and war-
farin among patients aged ≥ 65 years. To the best of our 
knowledge, no previous studies have compared net clinical 
benefits between rivaroxaban and warfarin.
Several real-world studies have focused on effective-
ness and safety comparisons between DOACs and war-
farin in an elderly NVAF population [11, 26–29]. Our 
previous study of the elderly Medicare population from 
2012 to 2014 consistent results of stroke/SE and major 
bleeding were found for the comparisons between DOACs 
and warfarin [11]. This study provides more recent and 
comprehensive analysis with updated data and added 
NCO and MACE outcomes. Using Medicare data from 
2010 to 2012, Graham et  al. [26] demonstrated that 
244 A. Amin et al.
1 3
Table 1  Baseline descriptive table before PSM
Std Difference greater than 10 is considered significant is given in bolditalic
CHA2DS2-VASc: congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thrombo-
embolism, vascular disease, age 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile 
INRs (international normalized ratio), elderly, drugs, and alcohol; PSM: propensity score matching; SD: standard deviation
a Std Difference = 100*|actual std diff|
b As the INR value was not available in the data, a modified HAS-BLED score was calculated using a range of 0 to 8
Warfarin 
(N = 81,410)
Apixaban (N = 38,466) Dabigatran (N = 18,162) Rivaroxaban (N = 60,133)
N/mean %/SD N/mean %/SD STDa N/mean %/SD STDa N/mean %/SD STDa
Age 78.9 7.5 78.3 7.5 6.9 77.0 7.0 25.0 77.6 7.3 16.8
65–74 26,091 32.0% 13,627 35.4% 7.1 7479 41.2% 19.0 23,255 38.7% 13.9
75–84 35,012 43.0% 15,916 41.4% 3.3 7607 41.9% 2.3 25,119 41.8% 2.5
≥ 85 20,307 24.9% 8923 23.2% 4.1 3076 16.9% 19.8 11,759 19.6% 13.0
Sex
Male 41,002 50.4% 18,581 48.3% 4.1 9338 51.4% 2.1 29,894 49.7% 1.3
Female 40,408 49.6% 19,885 51.7% 4.1 8824 48.6% 2.1 30,239 50.3% 1.3
Race
White 73,714 90.5% 35,311 91.8% 4.4 16,309 89.8% 2.5 54,642 90.9% 1.1
Black 4246 5.2% 1432 3.7% 7.2 785 4.3% 4.2 2336 3.9% 6.4
Hispanic 1037 1.3% 417 1.1% 1.8 290 1.6% 2.7 931 1.5% 2.3
Other 2413 3.0% 1306 3.4% 2.5 778 4.3% 7.1 2224 3.7% 4.1
Geographic region
Northeast 16,018 19.7% 6514 16.9% 7.1 3606 19.9% 0.4 10,596 17.6% 5.3
North Central 25,076 30.8% 7911 20.6% 23.6 4184 23.0% 17.6 13,341 22.2% 19.6
South 26,486 32.5% 17,229 44.8% 25.4 6953 38.3% 12.0 25,007 41.6% 18.8
West 13,745 16.9% 6791 17.7% 2.0 3387 18.6% 4.6 11,080 18.4% 4.0
Other 85 0.1% 21 0.1% 1.8 32 0.2% 1.9 109 0.2% 2.0
Medicaid dual-eligibility 18,908 23.2% 7488 19.5% 9.2 4268 23.5% 0.6 13,100 21.8% 3.5
Part D low-income subsidy 21,374 26.3% 8560 22.3% 9.3 4814 26.51% 0.6 14,734 24.5% 4.0
Baseline comorbidity
Deyo-Charlson comorbidity index 3.1 2.8 2.9 2.6 9.4 2.5 2.4 24.7 2.7 2.5 17.9
CHADS2 score 2.9 1.4 2.8 1.5 6.9 2.6 1.4 19.1 2.7 1.4 15.3
CHA2DS2-VASc score 4.7 1.7 4.6 1.8 5.5 4.4 1.7 20.2 4.5 1.7 14.3
HAS-BLED  scoreb 3.3 1.3 3.4 1.3 4.3 3.2 1.2 14.1 3.3 1.2 5.2
Baseline prior bleed 24,780 30.4% 11,807 30.7% 0.6 4731 26.0% 9.8 17,374 28.9% 3.4
Baseline prior stroke 12,496 15.3% 5280 13.7% 4.6 2159 11.9% 10.1 7385 12.3% 8.9
Congestive heart failure 29,326 36.0% 12,064 31.4% 9.9 5118 28.2% 16.9 17,287 28.7% 15.6
Diabetes 32,705 40.2% 13,602 35.4% 9.9 6737 37.1% 6.3 21,456 35.7% 9.3
Hypertension 71,416 87.7% 34,649 90.1% 7.5 15,964 87.9% 0.5 53,191 88.5% 2.3
Renal disease 21,021 25.8% 8599 22.4% 8.1 2892 15.9% 24.5 10,465 17.4% 20.6
Myocardial infarction 12,024 14.8% 5040 13.1% 4.8 1940 10.7% 12.3 7224 12.0% 8.1
Dyspepsia or stomach discomfort 17,317 21.3% 8699 22.6% 3.2 3607 19.9% 3.5 13,060 21.7% 1.1
Peripheral vascular disease 46,697 57.4% 22,742 59.1% 3.6 9689 53.3% 8.1 33,670 56.0% 2.8
Peripheral artery disease 20,131 24.7% 8932 23.2% 3.5 3635 20.0% 11.3 13,237 22.0% 6.4
Transient ischemic attack 6411 7.9% 3528 9.2% 4.6 1342 7.4% 1.8 4751 7.9% 0.1
Coronary artery disease 40,079 49.2% 19,962 51.9% 5.3 8367 46.1% 6.3 29,066 48.3% 1.8
Baseline medication use
Angiotensin converting enzyme inhibitor 30,102 37.0% 13,194 34.3% 5.6 6875 37.9% 1.8 21,463 35.7% 2.7
Amiodarone 5612 6.9% 4300 11.2% 15.0 1636 9.0% 7.8 5308 8.8% 7.2
Angiotensin receptor blocker 17,030 20.9% 10,056 26.1% 12.3 4498 24.8% 9.2 15,149 25.2% 10.2
Beta blockers 42,053 51.7% 22,070 57.4% 11.5 9756 53.7% 4.1 32,812 54.6% 5.8
H2-receptor antagonist 5699 7.0% 2828 7.4% 1.4 1214 6.7% 1.3 4181 7.0% 0.2
Proton pump inhibitor 24,020 29.5% 13,008 33.8% 9.3 5358 29.5% 0.0 19,152 31.8% 5.1
Anti-platelets 15,589 19.1% 9235 24.0% 11.8 3450 19.0% 0.4 13,101 21.8% 6.5
Statins 45,149 55.5% 23,492 61.1% 11.4 10,476 57.7% 4.5 34,956 58.1% 5.4
Inpatient admission 36,572 44.9% 15,168 39.4% 11.1 6830 37.6% 14.9 24,807 41.3% 7.4
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compared to warfarin, elderly NVAF dabigatran initia-
tors (aged ≥ 65 years) were associated with lower risks of 
ischemic stroke, ICH, and death; similar risk of acute MI 
and MB; and a higher major GI bleeding risk. Our results 
(over an updated time-frame) showed consistent trends for 
ICH and GI bleeding. However, the ischemic stroke risk 
was similar, and the MB risk was lower for dabigatran 
versus warfarin patients in our study. Using Humana data, 
Deitelzweig et al. [27] found that NVAF patients aged 
≥ 65 years with Medicare Advantage coverage who were 
treated with apixaban were associated with significantly 
lower risks of stroke/SE and MB compared to warfarin. 
This study noted consistent trends.
A few other real-world studies among DOACs and war-
farin have provided comparative effectiveness and safety 
information by conducting subgroup analyses for age sub-
groups [30–32]. Using MarketScan and Optum data from 
2010 to 2012, Seeger et al. showed that among patients aged 
65–74 years, compared to warfarin, dabigatran was asso-
ciated with similar risk for stroke and lower risk for MB; 
among those aged ≥ 75 years, dabigatran was associated with 
lower risk for stroke and similar risk for MB [30]. Using the 
MarketScan data from 2010 to 2014, Norby et al. [31] found 
that among patients aged ≥ 75 years, rivaroxaban was associ-
ated with a similar risk for ischemic stroke and MI, a lower 
ICH risk, and a higher GI bleeding risk compared to warfa-
rin. Using a pooled dataset, Li et al. [32] demonstrated that 
among elderly patients, apixaban was associated with similar 
(65–74) to lower (≥ 75) stroke/SE risk and a lower (65–74 
and ≥ 75) MB risk compared to warfarin. The comparisons 
between DOACs and warfarin in our study showed trends 
generally consistent with previous literature. However, more 
studies are needed to better understand effectiveness and 
safety profiles in elderly populations. Moreover, as DOAC 
use increases, further research will be necessary to assist in 
decision-making for such populations [33].
Despite growing evidence of improved safety with 
DOACs, warfarin is still widely used in high-risk NVAF 
populations [34]. Our study provides a current and compre-
hensive analysis comparing DOACs and warfarin regarding 
the risk of stroke/SE, MB, NCOs, and MACE among elderly 
US Medicare NVAF patients. Given the distinct clinical 
characteristics of the elderly NVAF population, the study 
results may add useful information to the literature to assist 
in disease management decision making.
This study has several limitations. Given its observational 
nature, confounding factors may have impacted the results. 
To control for potential confounders, a comprehensive list 
of baseline covariates was included in the PSM, including 
patient demographics and clinical characteristics. However, 
variables such as over-the-counter use of aspirin, serum cre-
atinine/creatinine clearance, and laboratory test result val-
ues are not captured in the Medicare data. As claims data 
analysis, the study may also be subject to coding errors and 
inaccurate or incomplete clinical information. For example, 
treatments recorded based on prescription claims include no 
DOAC Warfarin Hazard Ratio (95% CI) P-value
No. of events (incidence per 100 person-years)
Apixaban vs Warfarin
Stroke/SE 261 (1.11) 436 (1.52) 0.69 (0.59 – 0.81) <0.001
Ischemic 218 (0.92) 315 (1.10) 0.79 (0.66 – 0.94) 0.007
Hemorrhagic 32 (0.14) 101 (0.35) 0.38 (0.26 – 0.57) <0.001
SE 11 (0.05) 20 (0.07) 0.65 (0.31 – 1.35) 0.245
Major Bleeding 868 (3.70) 1,611 (5.66) 0.61 (0.57 – 0.67) <0.001
GI Bleeding 416 (1.76) 787 (2.74) 0.60 (0.53 – 0.67) <0.001
ICH 121 (0.51) 243 (0.84) 0.60 (0.48 – 0.75) <0.001
Other Bleeding 375 (1.59) 688 (2.40) 0.62 (0.55 – 0.71) <0.001
Dabigatran vs Warfarin
Stroke/SE 176 (1.39) 217 (1.54) 0.88 (0.72 – 1.07) 0.206
Ischemic 155 (1.22) 160 (1.13) 1.05 (0.84 – 1.31) 0.685
Hemorrhagic 15 (0.12) 47 (0.33) 0.35 (0.20 – 0.64) <0.001
SE 6 (0.05) 10 (0.07) 0.64 (0.23 – 1.75) 0.381
Major Bleeding 516 (4.08) 709 (5.07) 0.79 (0.71 – 0.89) <0.001
GI Bleeding 323 (2.54) 331 (2.35) 1.06 (0.91 – 1.23) 0.460
ICH 52 (0.41) 113 (0.80) 0.51 (0.37 – 0.71) <0.001
Other Bleeding 187 (1.47) 301 (2.14) 0.68 (0.57 – 0.81) <0.001
Rivaroxaban vs Warfarin
Stroke/SE 567 (1.36) 714 (1.67) 0.82 (0.73 – 0.91) <0.001
Ischemic 413 (0.9) 507 (1.18) 0.84 (0.73 – 0.95) 0.007
Hemorrhagic 125 (0.30) 171 (0.40) 0.76 (0.60 – 0.95) 0.017
SE 29 (0.07) 36 (0.08) 0.83 (0.51 – 1.35) 0.444
Major Bleeding 2,506 (6.08) 2,384 (5.63) 1.08 (1.02 – 1.14) 0.006
GI Bleeding 1,367 (3.29) 1,126 (2.64) 1.25 (1.16 – 1.35) <0.001
ICH 277 (0.66) 400 (0.93) 0.71 (0.61 – 0.83) <0.001
Other Bleeding 1,056 (2.54) 1,015 (2.38) 1.07 (0.98 – 1.17) 0.121
Favors DOAC Favors Warfarin
0.1 0.4 0.7 1 1.3 1.6 1.9
CI: confidence interval; DOAC: direct oral ancoagulant; GI: gastrointesnal; ICH: intracranial hemorrhage; SE: systemic embolism
Fig. 2  Incidence rate and hazard ratio of stroke/SE and major bleeding for propensity score-matched patients
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evidence of drug adherence. Moreover, since international 
normalized ratio values were not obtained, the quality of 
warfarin treatment could not be evaluated and the calcula-
tion for HAS-BLED score was modified. Moreover, proper 
dosage for DOACs based on age, renal function, and weight 
could not be assessed.
In summary, in the elderly Medicare population with 
NVAF, compared to warfarin, the DOACs were associated 
with a lower to similar risk of stroke/SE and MACE, but 
with varying comparative risks for MB and NCO.
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